Chicago—In patients with newly diagnosed advanced prostate cancer, initiating abiraterone at the same time as androgen deprivation therapy (ADT) is associated with a large overall survival (OS) benefit, according to results of two large, mutually reinforcing clinical trials. The results of these studies, presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO), are considered to have immediate relevance to patient management.
In one trial, called LATITUDE,